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Objective: Although calf muscle spasticity is often treated 
with botulinum toxin type-A, the effects on balance and gait 
are ambiguous. Hereditary spastic paraplegia is character-
ized by progressive spasticity and relatively mild muscle 
weakness of the lower limbs. It is therefore a good model 
to evaluate the functional effects of botulinum toxin type-A.
Design: Explorative pre-post intervention study.
Subjects: Fifteen subjects with pure hereditary spastic para-
plegia.
Methods: Patients with symptomatic calf muscle spasticity 
and preserved calf muscle strength received botulinum toxin 
type-A injections in each triceps surae (Dysport®, 500–750 
MU) followed by daily stretching exercises (18 weeks). Be-
fore intervention (T0), and 4 (T1) and 18 (T2) weeks there-
after, gait, balance, motor selectivity, calf muscle tone and 
strength were tested.
Results: Mean comfortable gait velocity increased from T0 
(0.90 m/s (standard deviation (SD) 0.18)) to T1 (0.98 m/s (SD 
0.20)), which effect persisted at T2, whereas balance and oth-
er functional measures remained unchanged. Calf muscle 
tone declined from T0 (median 2; range 1–2) to T1 (median 0; 
range 0–1), which effect partially persisted at T2 (median 1; 
range 0–2). Calf muscle strength did not change. 
Conclusion: Botulinum toxin type-A treatment and subse-
quent muscle stretching of the calves improved comfortable 
gait velocity and reduced muscle tone in patients with hered-
itary spastic paraplegia, while preserving muscle strength. 
Balance remained unaffected.
Key words: hereditary spastic paraplegia; botulinum toxin type-
A; muscle spasticity; gait; balance.
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IntROductIOn
Leg muscle spasticity is associated with deteriorated gait and 
balance performance in patients with upper motor neurone 
syndrome (uMnS) (1–3). In clinical practice, muscle spas-
ticity can be treated with spasmolytic drugs (4, 5), of which 
local injections with botulinum toxin type-A (BtX-A) are 
increasingly favoured over oral medication. BtX-A selectively 
impairs the neural activation of targeted muscles, particularly 
their involuntary activity due to spasticity (6). It has been 
demonstrated that BtX-A can successfully reduce spasticity, 
with the degree of improvement depending on the dosage 
(4, 5). However, the functional effects of this treatment are 
ambiguous (7). An important reason for this may be that most 
patients with uMnS not only experience “positive” signs, 
such as spasticity, but also “negative” signs, such as muscle 
weakness and muscle fatigue (8). the presence and severity of 
these negative signs may substantially influence the individual 
functional effects of BtX-A treatment. In order to improve 
clinical decision-making, it is thus important to understand 
the functional effects of BtX-A injections on both spasticity 
and motor control.
Patients with hereditary spastic paraplegia (HSP) constitute 
a good clinical model to investigate the effects of BtX-A 
treatment on motor control. HSP has a prevalence ranging 
between 2 and 10 per 100,000 persons and is characterized 
by slowly progressive leg muscle spasticity (9). the disease 
can be divided into “pure” and “complicated” phenotypes. In 
contrast to the complicated phenotype, patients with the pure 
form of HSP have relatively little somatosensory impairment 
and often only mild loss of muscle strength. these patients 
are mainly disabled by lower limb spasticity and associated 
muscle stiffness. thus, in these patients, functional effects of 
BtX-A treatment can be assessed relatively unconfounded by 
paresis and somatosensory impairment. 
to our knowledge, only a few uncontrolled studies have in-
vestigated the effects of BtX-A injections on motor control and 
functional performance in patients with HSP (10–12). these 
studies showed that BtX-A injections in the calves and/or hip 
adductors may lead to reduced levels of spasticity and some 
increase in gait velocity. However, functional improvements 
were found only in a limited number of participants, which 
may have been due to genetic heterogeneity (pure and compli-
cated phenotypes), inclusion of different degrees of severity of 
motor impairments, and varying BtX-A treatment protocols 
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(dosages and target muscles). In addition, these studies did not 
incorporate stretching exercises, which may have attenuated 
potential treatment effects. Indeed, a recent consensus on the 
application of BtX-A treatment recommended stretching the 
injected muscles after the treatment (4, 13). Lastly, previous 
studies did not investigate the effects of BtX-A on balance or 
other mobility-related skills in patients with HSP. 
Hence, the aim of this explorative study was to investigate 
the functional effects of BtX-A injections in the calves, fol-
lowed by 18 weeks of daily calf muscle stretching, in patients 
with pure HSP, symptomatic calf muscle spasticity and pre-
served calf muscle strength. It was hypothesized that BtX-A 
treatment and subsequent stretching would improve both 
gait velocity and balance performance due to a reduction in 
disabling calf muscle tone, with no change in muscle strength. 
MEtHOdS
Participants
All patients with symptomatic HSP who visited the outpatient depart-
ments of neurology and Rehabilitation Medicine of our university 
hospital during a period of one year were eligible. In addition, ac-
tive recruitment took place through the national patient organiza-
tion “Spierziekten nederland” and the hospital database. Inclusion 
criteria were: (i) having a form of autosomal dominant “pure” HSP 
(either genetically proven, i.e. subtypes SPG-4, SPG-3A and SPG-8, 
or based on family history); (ii) having clinical symptoms related to 
calf muscle spasticity (e.g. muscle cramps, stiffness, pain, clonus) 
either persistently or intermittently; (iii) being a community ambulator 
(Functional Ambulation categories score 5 (range 0–5)); (iv) having 
bilateral premature calf muscle activity during the loading and/or 
midstance phase of gait, as determined by surface electromyography 
(EMg); (v) having balance- and/or gait-related activity limitations in 
daily life based on the patient’s experiences; and (vi) aged between 18 
and 75 years. Exclusion criteria were: unilateral or bilateral: (i) calf 
muscle tone < 1 or > 2 on the Modified Ashworth Scale (MAS, range 
0–5) with the knee either flexed or extended; (ii) muscle strength of 
the calf or tibialis anterior muscle < 4 on the Medical Research council 
scale (MRc, range 0–5); (iii) passive ankle range of motion (PROM) 
< 10° dorsiflexion with the knee extended. 
A total of 77 eligible patients with pure HSP were identified and 
contacted by the primary investigator (Mdn). Of these, 46 patients 
were excluded based on a preliminary interview in which willing-
ness to participate and inclusion criteria 2, 3 and 5 were checked. 
thirty-one patients were invited to attend the outpatient department 
for additional, physical screening (Acg) and EMg recording during 
gait (Mdn). Based upon these examinations, 16 patients with pure 
HSP were eventually included (table I for characteristics). Reasons 
for exclusion of 15 patients were related to a MAS score of the calf 
< 1 (n = 5) or > 2 (n = 8), or a MRc score of the calf < 4 (n = 2). In 
addition, 10 healthy subjects with the same age and sex distribution 
participated as controls (only for assessments of gait velocity and 
dynamic posturography). All subjects gave their written informed 
consent prior to participation. the study was approved by the regional 
medical ethics committee and conducted according to the principles 
of the declaration of Helsinki (14).
Intervention
A solution of 500 Mu dysport® in 5 ml saline 0.9% was used. the 
total dosage was equal for both legs and was dependent on the level 
of spasticity. Patients with bilateral calf muscle tone MAS 1 received 
500 Mu in each leg, whereas patients with unilateral or bilateral calf 
muscle tone MAS 2 received 750 Mu in each leg. the BtX-A was 
distributed evenly over the 3 heads of the triceps surae, i.e. soleus (5 
sites) and medial (2 sites) and lateral (2 sites) heads of the gastroc-
nemius. Intramuscular electrical stimulation was used for optimal 
localization of the injection sites. 
during the 18-week intervention period, participants were instructed 
to perform 10 min stretching exercises of the calf muscles (with the 
knees both flexed and extended) twice daily. These exercises were 
demonstrated to all patients at the day of the injections until they 
were able to perform the exercises correctly themselves. during the 
intervention period, patients were asked every 2 weeks by the primary 
investigator (Mdn) whether they did their daily exercises. Partners 
were also stimulated to motivate the patients. no formal exercise 
diary was kept.
Outcome measures
the primary outcome measure was comfortable gait velocity, tested 
barefooted with the 10-m walking test (10Mwt) (15). the 10Mwt 
(15) has been shown to be a valid and reliable instrument in neuro-
logical patients. As the objective was also to record gait kinetics and 
kinematics (not reported in this study), we used a 6-camera Vicon 
motion analysis system (Vicon MX, Oxford Metrics, Oxford, uK) to 
measure gait speed. Reflective markers were placed on the skin accord-
ing to the PlugIngait full-body model (BodyBuilder, Vicon Motion 
Systems, Lake Forest, cA, uSA). From the marker position recordings, 
we calculated the walking speed over the middle 6 m (the first and 
last 2 m were discarded to allow for acceleration and deceleration).
Secondary outcomes were aimed at muscle tone and strength, leg 
motor selectivity, maximum gait velocity, timed-up-and-go perfor-
mance, functional balance, dynamic posturography, and balance 
confidence. Muscle tone of the calf and tibialis anterior (TA) was 
assessed using the Modified Ashworth Scale (MAS, range 0–5, (16)): 
0 = no increase in muscle tone; 1 = slight increase in tone, manifested 
by a catch and release or by minimal resistance at the end of range of 
motion (ROM); 2 = increase in tone, manifested by a catch followed 
by resistance through < 50% of ROM; 3 = marked increase in tone 
through > 50% of ROM; 4 = severe increase in tone through whole 
ROM (passive movement difficult); 5 = body segment rigid in flexion 
or extension (contracture). the calf muscle was tested with the knee 
both flexed (soleus) and extended (gastrocnemius). 
Muscle strength of the calf and tA was assessed with the Medical 
Research council scale (MRc, range 0–5): 0 = no movement observed; 
1 = only a trace or flicker of movement is seen or felt in the muscle or 
fasciculations are observed; 2 = muscle can move only if the resistance 
of gravity is removed; 3 = muscle strength is such that the joint can be 
moved against gravity only with the examiner’s resistance completely 
removed; 4 = muscle strength is reduced but movement is possible 
against resistance (i.e. being able to stand on the heels when testing 
the tA and to stand on the toes when testing the calf, bilaterally); 
5 = muscle contracts normally against full resistance (i.e. being able 
to stand on the heels and toes, unilaterally) (17); for scores 4 and 5 
balance support was allowed. 
In addition to clinical muscle testing, maximal voluntary isometric 
calf muscle strength was measured using the quantitative Muscle 
Assessment (QMA) fixed myometry testing system (Aeverll Medical 
LLc, gainesville, gA, uSA) (18). with this aim, patients were lying 
on a bench in a fixed position with the knees extended and ankle joints 
in a neutral position. In this position, patients had to plantarflex 1 ankle 
joint as firmly as possible against a rope attached to the forefoot and 
connected to a force transducer. this test was repeated 3 times for the 
left and the right ankle separately, allowing sufficient resting time in 
between the tests. the qMA score was the greatest strength (kg) of 
3 attempts for each side. 
Leg motor selectivity was tested using the Fugl Meyer Assessment 
(FMA) (19). the lower extremity part of the FMA was scored for each 
leg and expressed as a percentage of the maximum score (range 0–34). 
Maximum gait velocity was tested barefooted using the 10Mwt 
comparable to the test of comfortable gait velocity. Participants were 
instructed to walk as fast as possible without increasing their fall risk. 
In addition, the timed-up-and-go (tug) test (20) was performed 
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with shoes, but without walking aids. Functional balance was assessed 
barefooted with the BBS (range 0–56) (21). 
dynamic posturography was applied to test the postural responses to 
platform perturbations (for detailed descriptions of the characteristics 
of these perturbations see de niet et al. (22)). Patients stood barefoot 
on a moveable platform (size 1.2 × 1.8 m; BAAt Medical Products BV, 
Hengelo, the netherlands) with their eyes open, knees extended, and their 
feet at shoulder width. to prevent falls, they wore a safety harness sus-
pended from the ceiling. Platform rotations resulted in either dorsiflexion 
(toes-up perturbation (TUP)) or plantarflexion (toes-down perturbation 
(tdP)) at the ankle joints. the platform rotated at a maximum angular 
velocity of 51 °/s from a horizontal position to 3, 5, 7 or 9° inclination. 
In addition, platform translations (accelerations of 0.25, 0.5, 0.75 and 1 
m/s2) were applied in either the backward (forward perturbation (FP)) 
or forward (backward perturbation (BP)) direction. More specifically, 
tuPs were imposed to test the disinhibition of destabilizing calf muscle 
responses to stretch (as a key symptom of spasticity), whereas FPs were 
applied to test the potential effect of calf muscle weakness on stabilizing 
calf muscle responses. Each type of perturbation was repeated 4 times 
at each intensity level, so that a total number of 64 perturbations were 
imposed. A trial was classified as successful when the subject could 
sustain the perturbation without taking a step, grabbing for support, or 
bending the knees; otherwise it was classified as a failure. Trials at the 
highest intensity that were not performed by patients due to fatigue or fear 
of falling were also scored as failures. the overall balance performance 
was determined as the percentage of trials successfully executed for each 
type of perturbation (dynamic balance score).
In addition, to obtain a subjective measure of balance and mobil-
ity, the Activities-specific Balance Confidence Scale – short version 
(ABc-questionnaire) (23, 24) was used.
Procedure
within 3 weeks after inclusion, each patient with HSP was treated with 
bilateral BtX-A injections in the calf muscles by the same clinician 
(Acg). they were evaluated on all outcome measures by the same 
investigator (Mdn) 1 week before treatment (t0), 4 weeks after treat-
ment (t1) and 18 weeks after treatment (t2). t1 was set at 4 weeks after 
treatment, because at this time the physiological effects of BtX-A on 
spasticity were expected to have reached a maximum (25). thereafter, 
the effects of BtX-A were expected to diminish progressively until 
about 4 months after the injections. Hence, t2 was set at 18 weeks 
post-treatment to test the possible presence of a residual effect of the 
treatment not directly related to the physiological effects of BtX-A. 
Patients’ experiences
In addition to the formal outcome measures, patients were interviewed 
(semi-structured) at t2 for the treatment outcome in terms of functional 
gain (specifically focused on gait and balance) and general effects (e.g. 
perceived muscle stiffness). Finally, patients were asked whether they 
would consider continuation of treatment of the calf muscles with 
BtX-A (yes/no/undecided). 
Statistics
the bilateral scores for muscle tone (MAS), strength (MRc, qMA) 
and motor selectivity (FMA) were averaged into a single score for both 
sides of the body, resulting in an individual score for each assessment. 
continuous and interval measures (gait velocities, dynamic balance 
score, BBS, tug, qMA, FMA and ABc questionnaire) were tested 
for time effects (t0, t1 and t2) using one-way AnOVA for repeated 
measures. the other outcomes (MAS and MRc) were tested for time 
effects by means of the non-parametric Friedman’s test. to determine at 
what time interval significant Time effects occurred, we used post-hoc 
paired-samples t-tests and wilcoxon signed-rank tests with Bonferroni 
adjustments for continuous/interval and ordinal variables, respectively. 
Finally, the patients were divided in subgroups based on both the MAS 
and MRc scores of the calf at t0, and compared with regard to the 
change in gait velocity between t0 and t1 using a Mann-whitney U 
test. to compare gait velocity and dynamic balance performance of the 
patients with the performance by healthy controls, independent t-tests 
were used. the alpha level for all statistics was set at 0.05. Patients’ 
evaluations were qualitatively analysed.
RESuLtS
Participants
Every patient, except for 2, participated in all assessments. One 
patient was lost to follow-up after t1, because the measure-
ments were too demanding. Hence, 15 patients were analysed, 
for whom the patient characteristics are given in table I. One of 
these patients did not complete the dynamic balance assessment 
at t2 due to technical problems. Maximum gait velocity was 
set equal to comfortable velocity in 2 other patients, because 
they came close to falling during the examination of maximum 
gait velocity. According to the inclusion criteria, at t0 the MAS 
scores of the calf were 1 or 2 in all patients (MAS 2; gastrocne-
mius n = 8, soleus n = 6), whereas in most patients (n = 9) MRc 
scores of the calf were 5, indicating normal muscle strength. 
Primary outcome
table II summarizes the group results for all patients at all 
measurements. the comfortable gait velocity showed a main 
effect of time (F(2,28) = 11.93, p < 0.001), which consisted of a 
9% increase from baseline at t1 (p = 0.006) and a 12% increase 
from baseline at t2 (p = 0.002). the change in comfortable gait 
velocity did not differ between patients with an initial MAS 
1 score and those with an initial MAS 2 score of the calves 
(gastrocnemius, p = 0.209; soleus, p = 0.112) (Fig. 1). In ad-
dition, patients with MRc 5 of the calves at baseline did not 
show a different change in comfortable gait velocity compared 
with those with an initial MRc 4 grade (p = 0.088) (Fig. 2). 
Secondary outcomes
calf muscle tone diminished across time (gastrocnemius: 
χ2 (2, n = 15) = 26.462; soleus: χ2 (2, n = 15)=26.528, both 
table I. Characteristics of patients and controls
Patients (n = 15) controls (n = 10)
Age, years, mean (Sd) 
[range] 47.7 (12.3) [20–66] 46.1 (11.8) [22–63]
gender, male/female 12/3 7/3
gene
SPG-4
SPG-3A
SPG-8
Ad
8
1
1
5
MRc
5
4
9
6
Sensibility, mean (Sd) 
[range] 3.9 (2.0) [0–7]*
*Assessed with Rydel-Seiffer tuning fork.
MRc: Medical Research council scale; Ad: autosomal dominant 
inheritance; Sd: standard deviation.
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p < 0.001). this reduction partially persisted 
at t2 (gastrocnemius: p = 0.004; soleus: 
p = 0.002). calf muscle strength assessed 
with the MRC also showed a time effect (χ2 
(2, n = 15) = 8.4, p < 0.001). At t1, calf mus-
cle strength was reduced compared with t0 
(p = 0.046), but values returned to baseline 
level at t2 (p = 0.317). In contrast, muscle 
strength measured by qMA did not show any 
time effects (F(2,28) = 1.762, p = 0.190). Like-
wise, other clinical measures (FMA, tug, 
BBS, and ABc questionnaire) remained stable 
over time. In addition, maximum gait velocity 
did not show any time effect (F(2,24) = 0.010, 
p = 0.990) (table II).
Differences from healthy controls
At baseline, patients walked more slowly 
than healthy controls at both maximum (mean 
1.33 (standard deviation; Sd 0.34) vs 1.95 
(Sd 0.31), p < 0.001) and comfortable (mean 
0.90 (Sd 0.18) vs 1.32 (Sd 0.28), p < 0.001) 
velocity. Furthermore, dynamic balance per-
formance was worse in the patients than in the 
controls for all perturbation directions. none 
of these values showed significant changes 
across time (table II).
Patients’ experiences
table III summarizes the experiences men-
tioned after the treatment at t2. nine patients 
were very satisfied with the effects and re-
quested continuation of treatment of the calf 
muscles, whereas 3 patients were undecided 
whether they wanted to undergo this treatment 
again. three patients were disappointed in 
the effects and did not consider continuation 
of treatment. disappointment was related 
mainly to an experienced loss of calf muscle 
strength or loss of functional capacities. the 
experienced detrimental effects had all disap-
peared at t2.
dIScuSSIOn
the aim of this study was to evaluate the 
effects of BtX-A treatment and subsequent 
stretching of the calf muscles on gait and bal-
ance performance in patients with pure HSP 
who had symptomatic calf muscle spasticity 
and relatively preserved muscle strength. Our 
hypothesis that this treatment would improve 
gait velocity was partly corroborated. Only 
comfortable gait velocity improved by 9–12% 
after treatment. this effect was probably me-ta
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diated by a significant reduction in calf muscle tone, which 
may have promoted the rotation of the tibiae in the ankle joints 
during the midstance phase of gait, allowing a smoother roll-
off at both sides of the body. Indeed, a median improvement 
of 1 point on the MAS is generally considered to be clinically 
relevant (26). Interestingly, the beneficial effects of BTX-A 
treatment appeared to be independent of the initial level of calf 
muscle tone or strength, although a tendency was observed that 
patients with MRC 5 and MAS 1 scores of the calf benefitted 
most consistently (Fig. 1). Indeed, all 4 patients with such 
scores reached a clinically relevant change of ≥ 0.07 m/s in 
their comfortable gait velocity. This specific finding, as well as 
the overall pattern of results, indicates that the effects of BtX-
A treatment on muscle tone probably outweigh the possible 
detrimental (side) effects on muscle strength. the MRc scores 
of the calf suggested that, overall, a small temporary reduction 
in muscle force may have occurred 4 weeks after treatment. 
yet, the stable qMA values indicated that this temporary loss 
of calf muscle strength was relatively minor. Interestingly, the 
beneficial effects on both comfortable gait velocity and muscle 
tone persisted until 18 weeks after treatment, despite the fact 
that the biological effects of BtX-A are commonly thought to 
have ceased after this time interval. It may be that the stretch-
ing component of the treatment protocol was responsible for 
the observed long-term effects.
the observed reduction in muscle tone after BtX-A treat-
ment has been described extensively in previous studies (27, 
28), but the effect of BtX-A injections on muscle strength has 
received considerably less attention (10). Some studies have 
shown that patients may lose muscle strength, but the results 
of these studies were ambiguous (10) and not always focused 
on the treated muscles (11). In the present study, we assessed 
muscle strength with 2 separate tests; the most commonly 
used clinical assessment (MRc scoring) and a qMA. the 
clinical assessment showed that the median MRc score of the 
calf decreased from 5 to 4 at 4 weeks after treatment due to a 
temporary effect that was observed in 4 patients. However, the 
table III. Patients’ experiences after treatment (T2, n = 15)
n
Perceived effects
gait
Increase in efficacy (i.e. lower energy costs) 5
Less stumbling 2
Balance
Increase in balance 2
Other
Reduction in muscle cramps/spasms 9
Reduction in muscle stiffness (also expressed as more relaxed 
feeling in muscles) 4
Improved physical fitness 3
no effects perceived 3
Better rest at night 2
cessation of disability progression 1
(Transient) side-effects
Decreased balance confidence 2
Reduction in muscle strength 2
More stumbling 2
Fig. 1. change in gait velocity between baseline (t0) and t1 
represented for different scores on the Modified Ashworth 
Scale (MAS), Medical Research council scale (MRc) and 
quantitative Muscle Assessment (qMA) at baseline. * = change 
in comfortable gait velocity, O = change in maximum gait 
velocity. Dotted lines represent ± 0.07 m/s (defined as clinically 
relevant change in gait velocity). 
Fig. 2. change in gait velocity between t0 and t1 for various subgroups 
based on Modified Ashworth Scale (MAS) and Medical Research Council 
scale (MRc) scores of the calf at t0. * = change in comfortable gait velocity, 
O = change in maximum gait velocity. dotted lines represent ± 0.07 m/s 
(defined as clinically relevant change in gait velocity).
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QMA test did not show a significant decrement, which suggests 
that any reduction in calf muscle force after treatment was not 
merely temporary, but also clinically insignificant. This no-
tion is supported by the fact that the maximum gait velocity 
remained unchanged after treatment. Indeed, there were just as 
many patients showing an improvement as there were patients 
showing a decline in maximum gait velocity (Fig. 1). 
Besides a significant group effect, the comfortable gait veloc-
ity showed a clinically relevant change (≥ 0.07 m/s) in 10 of 
the 15 subjects (67%). this result indicates that patients with 
HSP may indeed experience a functional benefit from BTX-A 
injections in spastic calf muscles. At the same time, it indicates 
that such a benefit is not reached in every patient. Predicting 
which type of patient will experience functional benefits from 
BTX-A treatment has shown to be difficult (11). Also in this 
study, no predictors of success could be identified, although 
patients with initial MRc 5 and MAS 1 scores of the calves 
tended to exhibit the greatest improvement in comfortable gait 
velocity. Overall, it was reassuring that none of the patients 
with HSP showed a decline in comfortable gait velocity after 
BtX-A treatment of the calves, indicating the safety of this 
procedure with regard to ambulation. 
contrary to our hypothesis, balance performance and other 
functional measures remained unchanged after treatment. It 
may be that some of the outcome measures applied were not 
sensitive enough to detect functional improvements (29). On 
the other hand, one could question the clinical relevance of 
such small improvements. Another possibility is that, because 
of the chronic and progressive character of HSP, patients would 
need more time and repeated BtX-A treatment to be able to 
improve their balance-related skills and confidence. Future 
studies with repeated sessions of BtX-A injections in spastic 
muscles might shed light on this possibility. Probably the most 
important consideration for the lack of benefit with regard 
to balance and functional performance is that calf muscle 
spasticity may not be the main determinant of balance-related 
disabilities. Evidence for this notion has recently been found 
by a study in which patients with pure HSP were subjected 
to dynamic platform perturbations similar to those applied in 
the present study. It was found that a delay of approximately 
35 ms in the postural responses of the distal leg muscles (gas-
trocnemius, tibialis anterior) was the most important factor for 
explaining impaired balance responses to platform translations 
(30), while calf muscle spasticity was explanatory only for 
impaired responses to toes-up perturbations (22). this latter 
type or perturbations is, however, relatively rare in daily life.
Patients’ experiences
Most patients were completely (n = 9) or partially (n = 3) 
satisfied with the effects of treatment. Besides improvements 
in functional performance, several patients experienced less 
burden from physical problems such as spasms and muscle 
stiffness, better sleep, and/or a feeling of improved physical 
fitness. These subjective improvements are in line with previ-
ous studies in patients with HSP (10, 11), indicating that focal 
spasmolysis may have beneficial effects unrelated to functional 
improvements. 
Study limitations
An obvious limitation of the present study is the relatively 
small sample size, which is inherent in the inclusion of a 
homogeneous group of patients with pure HSP, as well as the 
lack of a control condition (e.g. placebo treatment). the use 
of rather stringent inclusion and exclusion criteria also limits 
the generalizability of our findings. Future research should 
preferably be multi-centred to increase the number of partici-
pants and allow a randomized controlled design. In addition, 
the functional effects of botulinum toxin should be assessed 
in relation to those of orthotic interventions. 
Conclusion
To our knowledge, this is the first study to investigate the 
functional effects of BtX-A injections in symptomatic spastic 
calf muscles in a homogeneous group of patients with pure HSP 
and with preserved calf muscle strength. we learned that this 
combined treatment gives a clinically significant and long-term 
improvement in comfortable gait velocity in most patients, 
probably mediated by a reduction in calf muscle tone, without 
a risk of inducing disabling calf muscle weakness or reducing 
maximum gait velocity. In addition, it became evident that 
improvement in balance-related skills and confidence cannot 
be expected within the same time-frame. Future studies might 
provide better insight into the underlying causes of the absence 
of functional effects on balance.
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